<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679753</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-0001-03</org_study_id>
    <nct_id>NCT04679753</nct_id>
  </id_info>
  <brief_title>Brainsway DTMS for Treatment of MDD Using iTBS</brief_title>
  <official_title>Brainsway Deep TMS System for Treatment of Major Depressive Disorder (MDD) Using Intermittent Theta Burst Stimulation (iTBS) Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainsway</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and effectiveness of the BrainsWay deep transcranial magnetic stimulation (DTMS)&#xD;
      device for the intended use of Major Depressive Disorder (MDD) using the intermittent&#xD;
      theta-burst (iTBS) stimulation protocol will be evaluated in a non-inferiority study,&#xD;
      comparing the iTBS treatment with the FDA cleared, (510(k) No. K122288) Brainsway DTMS device&#xD;
      to the High Frequency (HF) protocol using the same device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of Brainsway Deep TMS for the&#xD;
      treatment of Major Depressive Disorder using the iTBS stimulation protocol, by comparing it&#xD;
      to clinical data collected in the Brainsway randomized, controlled Multicenter study&#xD;
      (CTP-001-00), using the HF DTMS stimulation protocol used in support of the Brainsway DTMS&#xD;
      device 510(k) K122288.&#xD;
&#xD;
      In the post-marketing study, patients will be treated with an intermittent theta burst (iTBS)&#xD;
      protocol, using the same Brainsway DTMS device with the same H1-Coil. Furthermore, the&#xD;
      treatment paradigm is the same, consisting of TMS sessions performed daily for 5 weeks (20&#xD;
      DTMS sessions). The iTBS stimulation protocol consists of bursts of 3 pulses at 50 Hz, 5 Hz&#xD;
      bursts frequency, 2s on and 8s off, 600 pulses per session. The HF stimulation protocol was&#xD;
      delivered at 18 Hz, 120% stimulation intensity of the resting MT, 55 trains of 2s duration,&#xD;
      inter-train interval (ITI) of 20s, for 1980 pulses per session.&#xD;
&#xD;
      The clinical study design includes multiple measurements of safety and effectiveness&#xD;
      parameters.&#xD;
&#xD;
      The primary outcome measure is the change from baseline in HDRS-21 scores at the 5 week visit&#xD;
      (after 20 treatment sessions). The success criteria of the study is a non-inferiority margin&#xD;
      of 3.0 points.&#xD;
&#xD;
      The secondary efficacy endpoints of the study include evaluation of the response and&#xD;
      remission rates, based on HDRS-21 scores, at the 5 week visit, change in CGI-S score from&#xD;
      baseline to 6 weeks and response and remission rates based on CGI-S scores at the 6 week&#xD;
      visit.&#xD;
&#xD;
      Safety will be assessed at each treatment visit. Patients will be asked to report any adverse&#xD;
      event since their previous visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Brainsway Deep TMS with intermittent Theta Burst Stimulation (iTBS)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure was the change from baseline in HDRS-21 scores at the 5 week visit.</measure>
    <time_frame>5 weeks</time_frame>
    <description>Hamilton Depression Rating Scale (HDRS-21 items), where minimum score is 0 and maximum score is 53, and where higher scores mean a worse outcome. The success criteria of the study was a non-inferiority margin of 3.0 points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDRS-21 Response and Remission rates</measure>
    <time_frame>5 weeks</time_frame>
    <description>Evaluation of the response and remission rates based on HDRS-21 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-S score from baseline at the 6 week visit</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical Global Improvement - Severity Scale (CGI-S), where minimum score is 1 and maximum score is 7, and where higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S Response and Remission rates</measure>
    <time_frame>6 weeks</time_frame>
    <description>Evaluation of the response and remission rates based on CGI-S scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brainsway DTMS with High Frequency Stimulation (HF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brainsway DTMS with High Frequency Stimulation (HF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)</intervention_name>
    <description>Brainsway DTMS with iTBS</description>
    <arm_group_label>Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Brainsway DTMS with High Frequency (HF) Stimulation</intervention_name>
    <description>Brainsway DTMS with HF</description>
    <arm_group_label>Brainsway DTMS with High Frequency Stimulation (HF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients&#xD;
&#xD;
          -  Diagnosis of Major Depression Disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other significant Axis I psychiatric disorder with greater impairment than MDD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oluremi Adefolarin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SynapseTMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SynapseTMS</name>
      <address>
        <city>Yorkton</city>
        <state>Saskatchewan</state>
        <zip>S3N 4C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intermittent Theta Burst Stimulation</keyword>
  <keyword>iTBS</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

